Create a narrative

Xencor Community

NasdaqGM:XNCR Community

1 Narratives written by author
0 Comments on narratives written by author
7 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 10 Analysts

IBD Biologics And TL1A Programs Will Forge New Paths

Key Takeaways Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability. Strong clinical strategy and alignment with healthcare trends support sustained market expansion and robust future revenue growth.

US$28.20

FV

71.8% undervalued

14.60%

Revenue growth p.a.

0

0

6

14 days ago